<DOC>
	<DOCNO>NCT01007149</DOCNO>
	<brief_summary>This study assess change expression FcεRI receptor blood basophil dendritic cell 16 week treatment omalizumab compare placebo , adult patient non-atopic severe persistent asthma , uncontrolled despite optimal therapy .</brief_summary>
	<brief_title>Effect Omalizumab Patients With Severe Persistent Non-atopic Uncontrolled Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Severe persistent asthma follow characteristic : Uncontrolled accord Global Initiative Asthma ( GINA ) 2007 guideline least 2 exacerbation require systemic corticosteroid and/or least 1 hospitalization emergency room visit past year . Treated highdose inhale corticosteroid ( i.e . &gt; 1,000 µg beclometasone dipropionate equivalent per day ) plus inhaled longacting β2 agonist ( without maintenance oral corticosteroid ) . Nonatopic , i.e . negative blood multiallergic test negative Aspergillusspecific IgEradio allergosorbent blood test negative skin prick test battery common aeroallergens Current smoker smoke history stop less 3 year &gt; 10 pack year . Asthma exacerbation 4 week prior randomization . Active lung disease nonatopic asthma . Patients active cancer , suspicion cancer history cancer le 5 disease free year . Pregnant nursing ( lactate ) woman . Treatment omalizumab . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Severe asthma ,</keyword>
	<keyword>non-atopic ,</keyword>
	<keyword>omalizumab</keyword>
</DOC>